KYMRIAH (tisagenlecleucel) Patient Assistance Program
Don’t let the high cost of brand CAR-T cell therapy disrupt your treatment. We help eligible patients access Kymriah (tisagenlecleucel) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Kymriah (tisagenlecleucel) is FDA-approved for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in patients ≤25 years, relapsed/refractory large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy, and relapsed/refractory follicular lymphoma after at least two lines of systemic therapy. It is an autologous CD19-directed CAR-T cell therapy — a one-time treatment in qualified treatment centers.
- Without assistance, Kymriah costs commonly run approximately $475,000 per single infusion (drug cost alone), with total treatment costs (apheresis, hospital admission, supportive care) often $750,000–$1,500,000+.
- Through AffordMyPrescriptions, qualifying patients can access Kisqali for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Kymriah. Other CD19 CAR-T therapies for DLBCL include axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi). For B-ALL: brexucabtagene autoleucel (Tecartus, for adult relapsed/refractory B-ALL). Each CAR-T has slightly different efficacy and toxicity profiles.
What Is Kymriah Prescription Assistance Program?
The Kymriah Prescription Assistance Program is a manufacturer-sponsored initiative that helps cover the cost of Kymriah for qualifying patients based on income and insurance status. The program is designed for relapsed/refractory B-cell ALL or B-cell lymphoma patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating CAR-T coverage on your own means dealing with eligibility verification, complex insurance prior authorization (often requiring multiple appeals), CAR-T treatment center coordination, post-infusion long-term hospital care, and significant additional costs beyond the drug itself.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your CAR-T coverage application, working with the treatment center to maximize your access to manufacturer assistance and other resources.
Pharmacy Price Comparison
- Without assistance, Kymriah alone costs approximately $475,000 per infusion. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| CAR-T treatment center | $475,000 | Save substantially |
| Hospital inpatient cost | $200K–$500K | Save substantially |
| Total treatment cost | $750K–$1.5M | Save substantially |
| PAP-approved (drug) | $0 | Manufacturer PAP |
Medicare Part A/B coverage | Varies | Coverage applies |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Kymriah Prescription Program?
The Patient Assistance Program is free to apply for and can substantially reduce Kymriah drug costs for qualifying patients. Our $69.95/month service covers full advocacy across the complex CAR-T coverage landscape.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Kymriah:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $475,000 (drug alone); $750K–$1.5M total per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Kymriah assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Kymriah Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Kymriah:
Kymriah (tisagenlecleucel) is a one-time CAR-T cell therapy — your own T cells are collected, genetically engineered to express a chimeric antigen receptor (CAR) targeting CD19, expanded in a manufacturing facility, then infused back into you to attack CD19-expressing B-cell malignancies. It produces durable remissions in many patients with otherwise refractory disease.
How Kymriah Works:
CAR-T cell therapy is an advanced treatment that reprograms a patient’s own immune cells to selectively target and destroy B-cell cancer cells. The process involves collecting the patient’s T cells and genetically engineering them to express a chimeric antigen receptor that targets the CD19 protein. Once expanded and re-infused following chemotherapy, these modified cells multiply significantly within the body to attack the cancer. This targeted approach has helped many patients achieve long-lasting complete remission, though it can also cause serious toxicities.
Form and use:
Kymriah is administered as a single, one-time intravenous infusion delivered exclusively at a certified CAR-T treatment center. Prior to receiving the infusion, patients undergo three to five days of lymphodepleting chemotherapy, with the entire timeline from cell collection to infusion taking three to six weeks. Following the infusion, patients are hospitalized for a minimum of seven to ten days so providers can closely monitor them for severe complications. To ensure patient safety, the medication tocilizumab must be kept on standby to immediately manage potential cytokine release syndrome.
Generic availability:
There is currently no biosimilar version of Kymriah available on the market. Depending on the patient’s specific age, medical history, and institutional capabilities, healthcare providers may consider alternative CD19-targeted CAR-T therapies like Yescarta, Breyanzi, or Tecartus. Yescarta and Breyanzi serve as options for large B-cell and follicular lymphomas, while Tecartus is utilized specifically for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Warnings:
Kymriah carries prominent boxed warnings for life-threatening risks, specifically cytokine release syndrome and severe neurologic toxicities like ICANS. The treatment also places patients at high risk for serious infections due to prolonged low blood cell counts and long-term depletion of healthy B cells, which often requires ongoing antibody replacement therapy. Furthermore, it carries risks for tumor lysis syndrome, allergic reactions, and secondary T-cell malignancies. Because of these severe safety concerns, the therapy is strictly restricted to certified centers operating under a mandatory REMS safety program.
FAQ (Frequently Asked Questions)
How Much Does Kymriah Cost Without Insurance?
Kymriah’s drug cost is approximately $475,000 per single infusion. Total treatment costs (including apheresis, lymphodepleting chemotherapy, hospitalization, post-infusion care) often run $750,000–$1,500,000+. Through AffordMyPrescriptions and the manufacturer PAP, qualifying patients may have substantial cost coverage — but the cost magnitude makes coordination with the CAR-T treatment center, insurance, and multiple support programs essential. Our $69.95/month service covers full advocacy.
What Is CAR-T Cell Therapy?
CAR-T (chimeric antigen receptor T-cell) therapy is a personalized cellular therapy. Your own T cells are collected, genetically engineered to express a receptor that recognizes a cancer marker (CD19 for B-cell malignancies), expanded over weeks, then infused back into you. The modified T cells then expand massively in your body and kill the cancer cells. It is a one-time treatment that can produce durable remissions in patients with otherwise refractory disease.
Who Is Eligible For Kymriah?
FDA-approved indications include: pediatric/young adult (≤25 years) relapsed/refractory B-cell ALL, adult relapsed/refractory DLBCL after ≥2 lines of therapy, adult relapsed/refractory follicular lymphoma after ≥2 lines of therapy. Eligibility within these indications also depends on performance status, organ function, prior therapies, and absence of certain comorbidities. Treatment is at certified CAR-T centers.
What Are CRS And ICANS?
Cytokine release syndrome (CRS): a systemic inflammatory response from massive CAR-T cell expansion and cytokine release — fever, hypotension, hypoxia, organ dysfunction. Managed with tocilizumab (anti-IL-6R) and supportive ICU-level care. ICANS (immune effector cell-associated neurotoxicity syndrome): neurologic dysfunction — confusion, seizures, encephalopathy. Both typically peak 1–14 days after CAR-T infusion. Both are managed in specialized centers with experienced teams.
What About The Secondary T-Cell Malignancy Risk?
In 2024, the FDA added a boxed warning to all CD19 CAR-T therapies (Kymriah, Yescarta, Breyanzi, Tecartus, etc.) for risk of T-cell malignancies — including some cases where the malignancy contained the CAR transgene, suggesting causation. The absolute risk appears low (<1%) compared to the substantial benefit in refractory disease, but lifelong monitoring is recommended.
Can I Get Kymriah Through The PAP If I Have Medicare?
Medicare covers CAR-T therapy with national coverage determination — but coverage details and out-of-pocket costs vary. Medicare Part A covers the inpatient hospitalization; the drug component depends on Part B or specific NCD provisions. The manufacturer’s PAP may help with copays or other costs. Coordination with the treatment center’s financial team is essential.
What If My Application Is Denied?
If denied, we explore alternatives — other CD19 CAR-T products (Yescarta, Breyanzi, Tecartus) with their own access programs, clinical trials, the manufacturer’s copay program for commercially insured patients, charity care at the treatment center, and independent foundations such as the Leukemia & Lymphoma Society, Lymphoma Research Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are facing the high cost of Kymriah CAR-T therapy, our team may be able to help you access manufacturer assistance and coordinate with your treatment center. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.